(12) United States Patent (10) Patent No.: US 8,357,385 B2 Laronde Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) United States Patent (10) Patent No.: US 8,357,385 B2 Laronde Et Al US00835.7385B2 (12) United States Patent (10) Patent No.: US 8,357,385 B2 LaRonde et al. (45) Date of Patent: *Jan. 22, 2013 (54) COMBINATION THERAPY FOR THE FOREIGN PATENT DOCUMENTS TREATMENT OF BACTERAL INFECTIONS CA 2243 649 8, 1997 CA 2417 389 2, 2002 Inventors: Frank LaRonde, Toronto (CA); Hanje CA 2438 346 3, 2004 (75) CA 2539 868 4/2005 Chen, Toronto (CA); Selva Sinnadurai, CA 2467 321 11, 2005 Scarborough (CA) CA 2611 577 9, 2007 (73) Assignee: Interface Biologics Inc., Toronto (CA) OTHER PUBLICATIONS Bu et al. A Comparison of Topical Chlorhexidine, Ciprofloxacin, and (*) Notice: Subject to any disclaimer, the term of this Fortified Tobramycin/Cefazolin in Rabbit Models of Staphylococcus patent is extended or adjusted under 35 and Pseudomonas Keratitis. Journal of Ocular Pharmacology and U.S.C. 154(b) by 377 days. Therapeutics, 1997 vol. 23, No. 3, pp. 213-220.* Martin-Navarro et al. The potential pathogenicity of chlorhexidine This patent is Subject to a terminal dis sensittive Acanthamoeba strains isolated from contact lens cases claimer. from asymptomatic individuals in Tenerife, Canary Islands, Spain. Journal of Medical Microbiology. 2008. vol. 57, pp. 1399-1404.* (21) Appl. No.: 12/419,733 Craig et al., Modern Pharmacology. 4' Edition: 545-547, 555-557. 567, 569, 583-586, 651-654, and 849-851. (1994). Filed: Apr. 7, 2009 Jones et al., “Bacterial Resistance: A Worldwide Problem.” Diagn. (22) Microbiol. Infect. Dis. 31:379-388 (1998). Murray, "Antibiotic Resistance.” Adv. Intern. Med. 42:339-367 (65) Prior Publication Data (1997). US 201O/OO62974 A1 Mar. 11, 2010 Nakae, “Multiantibiotic Resistance Caused by Active Drug Extru sion in Pseudomonas aeruginosa and Other Gram-Negative Bacte ria.” Microbiologia. 13:273-284 (1997). Related U.S. Application Data International Search Report (PCT/CA2009/000446), dated Jun. 8, Provisional application No. 61/123,231, filed on Apr. 2009. (60) International Preliminary Report on Patentability and Written Opin 7, 2008. ion of the Searching Authority (PCT/CA2009/000446), dated Oct. (51) Int. C. 21, 2010. A6DF 3/00 (2006.01) * cited by examiner A6 IK3I/74 (2006.01) (52) U.S. Cl. ..................................... 424/422; 424/78.17 Primary Examiner — Marcela M Cordero Garcia (58) Field of Classification Search ........................ None (74) Attorney, Agent, or Firm — Clark & Elbing LLP: See application file for complete search history. Kristina Bieker-Brady (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS The invention features a method for treating a Subject diag 2,631,146 A * 3/1953 Weidenheimer et al. ..... 540,345 nosed with, or at risk of developing, a bacterial infection by 6,432,389 B1* 8/2002 Hansenne et al. .............. 424,59 administering to the Subject a combination of biologically 2004/0039031 A1* 2/2004 Cugnardey et al. .. 514,354 active agents. 2007/0020320 A1 1/2007 David et al. ................... 424,445 2010.0034.862 A1 2/2010 Laronde et al. ............... 424/423 6 Claims, No Drawings US 8,357,385 B2 1. 2 COMBINATION THERAPY FOR THE agent selected from fluoroquinolones, aminoglycosides, TREATMENT OF BACTERAL INFECTIONS B-lactams, glycopeptide antibiotics, Sulfonamides, and anti fungal azoles. CROSS-REFERENCE TO RELATED The invention further features a composition including a APPLICATIONS biodegradable polymer having a first repeating unit and a second repeating unit, the first repeating unit including a This application claims benefit from U.S. Provisional membrane active biocide and the second repeating unit Application No. 61/123,231, filed Apr. 7, 2008, hereby incor including a second agent selected from fluoroquinolones, porated by reference. aminoglycosides, B-lactams, glycopeptide antibiotics, Sul 10 fonamides, and antifungal azoles. The invention also features a composition including (i) a BACKGROUND OF THE INVENTION biodegradable polymer including a repeating unit including a The present invention relates to the field of antibacterial membrane active biocide and (ii) a second agent selected therapy. from fluoroquinolones, aminoglycosides, 3-lactams, glyco 15 peptide antibiotics, Sulfonamides, and antifungal azoles. The use of antibiotics by humans can be seen as an evolu In a related aspect the invention features a composition tionary experiment of enormous magnitude, a window from including (i) a biodegradable polymer including a repeating which to view not-quite-natural selection operating in real unit including a secondagent selected from fluoroquinolones, time. Within 50 years, the number of species and strains of aminoglycosides, B-lactams, glycopeptide antibiotics, Sul pathogenic and commensal bacteria resistant to antibiotics fonamides, and antifungal azoles and (ii) a membrane active and the number of antibiotics to which they are resistant has biocide. increased virtually monotonically world-wide. As a result, The invention further features a composition including (i) infections that had been readily treatable by chemotherapy a first biodegradable polymer including a repeating unit may no longer be so. It is clear that the evolution and spread including a membrane active biocide and (ii) a second biode of resistance can be attributed to the use and overuse of 25 gradable polymer including a repeating unit including a sec antibiotics. Increased resistance of bacterial infections to ond agent selected from fluoroquinolones, aminoglycosides, antibiotic treatment has been extensively documented and has B-lactams, glycopeptide antibiotics, Sulfonamides, and anti now become a generally recognized medical problem, par fungal azoles. ticularly with nosocomial infections. See, for example, Jones The invention further features a method of reducing bac et al., Diagn. Microbiol. Infect. Dis. 31:379-388, 1998; Mur 30 terial growth on a Surface by contacting the Surface with a ray, Adv. Intern. Med. 42:339-367, 1997; and Nakae, Micro composition including a membrane active biocide and a sec biologia 13:273-284, 1997. ond agent selected from fluoroquinolones, aminoglycosides, Throughout the developed world there is public and gov B-lactams, glycopeptide antibiotics, Sulfonamides, and anti ernmental concern about the increasing prevalence of antimi fungal azoles in amounts that together are effective to reduce 35 bacterial growth. crobial resistance to chemotherapy in bacteria that cause dis The invention also features a method of reducing bacterial eases in humans. Many pathogens exist for which there are growth on a Surface by coating the Surface with a biodegrad few effective treatments, and the number of strains resistant to able polymer including a first repeating unit and a second available drugs is continually increasing. New antimicrobial repeating unit, the first repeating unit including a membrane agents and improved methods are thus needed for the treat 40 active biocide and the second repeating unit including a sec ment and prevention of infections by Such pathogens. ond agent selected from fluoroquinolones, aminoglycosides, B-lactams, glycopeptide antibiotics, Sulfonamides, and anti SUMMARY OF THE INVENTION fungal azoles. The invention further features a method of reducing fungal We have discovered that a combination of a membrane 45 growth on a surface by contacting the Surface with a compo active biocide (e.g., chlorhexidine) and a second agent sition including a membrane active biocide and a second selected from fluoroquinolones, aminoglycosides, B-lactams, agent selected from fluoroquinolones, aminoglycosides, glycopeptide antibiotics, Sulfonamides, and antifungal azoles B-lactams, glycopeptide antibiotics, Sulfonamides, and anti is more effective in treating bacterial infections and reducing fungal azoles in amounts that together are effective to reduce bacterial growth than either agent alone. We have also dis 50 fungal growth. covered that a combination of a Sulfonamide (e.g., Sul The invention also features a method of reducing fungal famethoxazole) and a second agent selected from B-lactams growth on a Surface by coating the Surface with a biodegrad and antifungal azoles is more effective in treating bacterial able polymer including a first repeating unit and a second infections and reducing bacterial growth than either agent repeating unit, the first repeating unit including a membrane alone. Thus, the invention features compositions, methods, 55 active biocide and the second repeating unit including a sec and kits including these effective combinations, which can be ond agent selected from fluoroquinolones, aminoglycosides, useful for the treatment and prevention of infections. B-lactams, glycopeptide antibiotics, Sulfonamides, and anti Accordingly, in a first aspect the invention features a com fungal azoles. position including a membrane active biocide and a second In certain embodiments of the above methods, the surface agent selected from fluoroquinolones, aminoglycosides, 60 is, for example, a Surface of an implantable medical device B-lactams, glycopeptide antibiotics, Sulfonamides, and anti (e.g., a cardiac-assist device, a catheter, a stent, a prosthetic fungal azoles in amounts that together are sufficient in vivo to implant, a Suture, a cuff, a mesh, a hernia patch, a wound treat a bacterial infection. dressing, a bandage, an artificial sphincter, or a drug delivery In a related aspect, the invention features a biodegradable device) or any other surface described herein. polymer including a first repeating unit and a second repeat 65 The invention also features a method of treating a bacterial ing unit,
Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Repurposing Drug Scaffolds: a Tool for Developing Novel Therapeutics with Applications in Malaria and Lung Cancer
    Repurposing Drug Scaffolds: A Tool for Developing Novel Therapeutics with Applications in Malaria and Lung Cancer A Thesis Submitted by: Hannah Elizabeth Cook In partial fulfilment of the requirements for the degree of: Doctor of Philosophy September 2018 Supervisors: Professor Matthew J. Fuchter & Professor Anthony G. M. Barrett Department of Chemistry Imperial College London 2 Declaration of Originality I, Hannah Cook, hereby confirm that the work presented within this thesis is entirely my own, conducted under the supervision of Professor Matthew J. Fuchter and Professor Anthony G. M. Barrett, at the Department of Chemistry, Imperial College London, unless otherwise stated. All work performed by others has been acknowledged within the text and referenced where appropriate. Hannah E. Cook September 2018 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 3 Abstract The definition of repurposing in the context of drug discovery encompasses a variety of strategies designed to redirect current therapeutic knowledge towards new disease indications. This approach can be successful for the design of new drugs to treat diseases of the developing world such as Malaria, where there are limited resources to fund new drug discovery campaigns. Moreover, it can be used to decrease the drug development time for diseases in which there is high drug attrition rates coupled with high mortality rates, which is the case for some cancers.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma by Andrea Shergalis
    Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma By Andrea Shergalis A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Medicinal Chemistry) in the University of Michigan 2020 Doctoral Committee: Professor Nouri Neamati, Chair Professor George A. Garcia Professor Peter J. H. Scott Professor Shaomeng Wang Andrea G. Shergalis [email protected] ORCID 0000-0002-1155-1583 © Andrea Shergalis 2020 All Rights Reserved ACKNOWLEDGEMENTS So many people have been involved in bringing this project to life and making this dissertation possible. First, I want to thank my advisor, Prof. Nouri Neamati, for his guidance, encouragement, and patience. Prof. Neamati instilled an enthusiasm in me for science and drug discovery, while allowing me the space to independently explore complex biochemical problems, and I am grateful for his kind and patient mentorship. I also thank my committee members, Profs. George Garcia, Peter Scott, and Shaomeng Wang, for their patience, guidance, and support throughout my graduate career. I am thankful to them for taking time to meet with me and have thoughtful conversations about medicinal chemistry and science in general. From the Neamati lab, I would like to thank so many. First and foremost, I have to thank Shuzo Tamara for being an incredible, kind, and patient teacher and mentor. Shuzo is one of the hardest workers I know. In addition to a strong work ethic, he taught me pretty much everything I know and laid the foundation for the article published as Chapter 3 of this dissertation. The work published in this dissertation really began with the initial identification of PDI as a target by Shili Xu, and I am grateful for his advice and guidance (from afar!).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Guidelines on Urinary and Male Genital Tract Infections
    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
    [Show full text]
  • (OTC) Antibiotics in the European Union and Norway, 2012
    Perspective Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012 L Both 1 , R Botgros 2 , M Cavaleri 2 1. Public Health England (PHE), London, United Kingdom 2. Anti-infectives and Vaccines Office, European Medicines Agency (EMA), London, United Kingdom Correspondence: Marco Cavaleri ([email protected]) Citation style for this article: Both L, Botgros R, Cavaleri M. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012. Euro Surveill. 2015;20(34):pii=30002. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.34.30002 Article submitted on 16 September 2014 / accepted on 09 February 2015 / published on 27 August 2015 Antimicrobial resistance is recognised as a growing throughout the EU; however, there are still consider- problem that seriously threatens public health and able differences in Europe due to the different health- requires prompt action. Concerns have therefore been care structures and policies (including the extent of raised about the potential harmful effects of making pharmacist supervision for OTC medicines), reimburse- antibiotics available without prescription. Because of ment policies, and cultural differences of each Member the very serious concerns regarding further spread of State. Therefore, the availability of OTC medicines var- resistance, the over-the-counter (OTC) availability of ies in the EU and products sold as POM in certain coun- antibiotics was analysed here. Topical and systemic tries can be obtained as OTC medicines in others. OTC antibiotics and their indications were determined across 26 European Union (EU) countries and Norway As risk minimisation is an important criterion for some by means of a European survey.
    [Show full text]